Express Scripts repeats FY14 adjusted EPS view $4.82-$4.94, consensus $4.87 Repeats FY14 adjusted EBITDA view $6.775B-$6.975B. Sees FY14 adjusted EBITDA per adjusted claim $5.20-$5.30. Sees FY14 EPS growth of 17%-20% excluding UNH. Sees FY14 adjusted claims 1.27B-1.33B. Comments from slides that are being presented at the Bank of America Merrill Lynch Healthcare Conference.
Express Scripts says 'scrutinizing' every Valeant prescription, Bloomberg says According to Bloomberg, the Express Scripts Chief Medical Officer said in an interview that Valeant prescriptions are getting "extra scrutiny."